Loading…
Employees: 82
Size Dong-A Socio (000640.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $425M, the 375th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩87,000 on 6 Nov 2026.
Performance Over six months the shares fell 11.1%, against -15.9% for the median peer and -24.5% for the South Korea market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 10.1% over the last twelve months (peer median +3.1%); the operating margin is 7.1% (peer median 2.4%).
Valuation It trades at 7.6× forward earnings against a peer median of 21.4× (2nd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.52T | ₩1.43T | ₩1.33T | ₩1.13T | ₩1.01T |
| Revenue growth | — | +7% | +18% | +12% | — |
| Gross profit | ₩470B | ₩439B | ₩396B | ₩364B | ₩283B |
| EBITDA | ₩200B | ₩193B | ₩171B | ₩151B | ₩109B |
| Net income | ₩85.3B | ₩90.9B | ₩58.0B | ₩58.0B | ₩11.2B |
| Free cash flow | ₩171B | ₩154B | ₩12.2B | -₩3.54B | ₩9.12B |
| Capital expenditure | ₩63.1B | ₩58.6B | ₩71.9B | ₩153B | ₩78.6B |
| Total debt | ₩687B | ₩663B | ₩740B | ₩692B | ₩552B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000640.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | -12.2% | 8th highest of 21 |
| 6-month return | -11.1% | -15.9% | 9th highest of 20 |
| Distance from 52-week high | -28.6% | -37.4% | 8th highest of 21 |
| Revenue growth (TTM) | +10.1% | +3.1% | 9th highest of 19 |
| Operating margin | 7.1% | 2.4% | 9th highest of 19 |
| Forward P/E | 7.6× | 21.4× | 2nd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -8.8% | 4.7% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +12.8% | +9.2% | 3rd highest of 9 |
| Hurdle (Req g minus delivered) | -21.6 pp | -6.6 pp | 2nd least demanding of 9 |
| ROIC minus cost of capital | -0.3 pp | -2.2 pp | 7th highest of 17 |
| EV / EBITDA | 5.3× | 14.0× | 2nd cheapest of 9 |
| Net debt / EBITDA | 2.4× | -0.0× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 7.6× | -8.8% | +12.8% |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 21.7× | 2.8% | +0.3% |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 24.2× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | n/a | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 21.2× | 9.9% | +6.7% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 18.9× | 19.7% | +3.5% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | n/a | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | n/a | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 54.8× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 14.4× | -4.5% | +12.1% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | n/a | -0.4% | +11.2% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | n/a | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | n/a | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 6.2× | -16.9% | +7.2% |